ArticleInfectious diseases and therapy2024

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.

F D Richard Hobbs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.